Kind B, Fattinger K, Krähenbühl S, Meier-Abt P J
Abteilung Klinische Pharmakologie und Toxikologie, Universitätsspital Zürich.
Praxis (Bern 1994). 1996 Nov 12;85(46):1490-2.
We describe a patient with chronic depression who was treated with the selective serotonin-reuptake-inhibitor sertraline. Following surgery, the patient developed severe nausea and vomiting, necessitating an efficient antiemetic treatment, possibly including the 5-HT3-receptor antagonist ondansetrone. Because both drugs, sertraline and ondansetrone, interact with the serotonin system at the synapsis, a possible interaction was discussed. Since the effect of the selective serotonin-reuptake inhibitors mainly depends on 5-HT1 and 5-HT2-receptors, a pharmacodynamic interaction between an 5-HT3-antagonist and a serotonin-reuptake-inhibitor at the synapsis leading to the relapse of depression seems to be very unlikely. There exist also no conclusive data suggesting a clinically relevant pharmacokinetic interaction between the two drugs. A treatment with ondansetrone was considered to be safe in this patient.
我们描述了一位患有慢性抑郁症的患者，其接受了选择性5-羟色胺再摄取抑制剂舍曲林的治疗。手术后，该患者出现了严重的恶心和呕吐，需要进行有效的止吐治疗，可能包括5-羟色胺3受体拮抗剂昂丹司琼。由于舍曲林和昂丹司琼这两种药物都在突触处与5-羟色胺系统相互作用，因此讨论了可能存在的相互作用。由于选择性5-羟色胺再摄取抑制剂的作用主要取决于5-羟色胺1和5-羟色胺2受体，所以5-羟色胺3拮抗剂与5-羟色胺再摄取抑制剂在突触处发生药效学相互作用导致抑郁症复发的可能性似乎非常小。也没有确凿的数据表明这两种药物之间存在具有临床相关性的药代动力学相互作用。在该患者中，使用昂丹司琼治疗被认为是安全的。
